TY - JOUR
T1 - Phase i clinical trial of pegylated liposomal doxorubicin and docetaxel in patients with advanced solid tumors
AU - Iqbal, Syma
AU - Tsao-Wei, Denice D.
AU - Quinn, David I.
AU - Gitlitz, Barbara J.
AU - Groshen, Susan
AU - Aparicio, Ana
AU - Lenz, Heinz Josef
AU - El-Khoueiry, Anthony
AU - Pinski, Jacek
AU - Garcia, Agustin A.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/2
Y1 - 2011/2
N2 - Objective: The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors. Patients and Methods: Patients were treated with intravenous PLD on day 1 and T on days 1, 8, and 15. Once the MTD was reached the schedule of PLD was changed to days 1 and 15 to explore an alternative and potentially more manageable dosing schedule. Results: Thirty-two patients were enrolled. A total of 106 cycles (median, 2 cycles; range, <1-13 cycles) of chemotherapy were administered. Three patients experienced dose-limiting toxicities which were stomatitis, anorexia, esophagitis, neutropenic fever, fatigue, and muscular weakness. When PLD was given on day 1, the MTD was PLD 33 mg/m2 and T 30 mg/m 2. MTD was not reached when PLD was administered on days 1 and 15: only 1 of 6 patients treated with PLD 20 mg/m2 and T 30 mg/m 2 developed dose-limiting toxicities. The most common grade 3 or 4 hematologic toxicity was grade 3 neutropenia in 5 patients and grade 4 in 5. Two patients developed neutropenic fever. The most common grade 3 or 4 nonhematologic toxicity was grade 3 fatigue in 9 patients and grade 4 in 1. There was 1 confirmed PR, 2 unconfirmed PRs, and 12 patients with Sd. Conclusions: This combination of PLD and T was found to be feasible and tolerable. The recommended dose for phase II studies is PLD 20 mg/m2 on days 1 and 15 and T 35 mg/m2 on days 1, 8, and 15.
AB - Objective: The primary objective of this study was to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) and docetaxel (T) administered in 4 week cycles in patients with advanced solid tumors. Patients and Methods: Patients were treated with intravenous PLD on day 1 and T on days 1, 8, and 15. Once the MTD was reached the schedule of PLD was changed to days 1 and 15 to explore an alternative and potentially more manageable dosing schedule. Results: Thirty-two patients were enrolled. A total of 106 cycles (median, 2 cycles; range, <1-13 cycles) of chemotherapy were administered. Three patients experienced dose-limiting toxicities which were stomatitis, anorexia, esophagitis, neutropenic fever, fatigue, and muscular weakness. When PLD was given on day 1, the MTD was PLD 33 mg/m2 and T 30 mg/m 2. MTD was not reached when PLD was administered on days 1 and 15: only 1 of 6 patients treated with PLD 20 mg/m2 and T 30 mg/m 2 developed dose-limiting toxicities. The most common grade 3 or 4 hematologic toxicity was grade 3 neutropenia in 5 patients and grade 4 in 5. Two patients developed neutropenic fever. The most common grade 3 or 4 nonhematologic toxicity was grade 3 fatigue in 9 patients and grade 4 in 1. There was 1 confirmed PR, 2 unconfirmed PRs, and 12 patients with Sd. Conclusions: This combination of PLD and T was found to be feasible and tolerable. The recommended dose for phase II studies is PLD 20 mg/m2 on days 1 and 15 and T 35 mg/m2 on days 1, 8, and 15.
KW - docetaxel
KW - liposomal doxorubicin
KW - phase I
UR - http://www.scopus.com/inward/record.url?scp=79951676595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951676595&partnerID=8YFLogxK
U2 - 10.1097/COC.0b013e3181cae766
DO - 10.1097/COC.0b013e3181cae766
M3 - Article
C2 - 20142723
AN - SCOPUS:79951676595
SN - 0277-3732
VL - 34
SP - 27
EP - 31
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 1
ER -